Read More: eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient


Mark Pruzanski, M.D.

Board Director

Dr. Pruzanski has more than 25 years of experience as a life sciences executive, entrepreneur and investor. He founded Intercept Pharmaceuticals and was the company’s Chief Executive Officer until 2021, having led its evolution from a drug discovery stage to global development and commercial organization. He has been a member of the board of several private and public biotechnology companies and currently serves as a director of Intercept and Equillium, as well as the Emerging Companies Section of the Biotechnology Innovation Organization (BIO) and the Foundation for Defense of Democracies, a non-profit policy institute focusing on foreign policy and national security.

Dr. Pruzanski previously co-founded and was a venture partner at Apple Tree Partners and prior to that was an entrepreneur-in-residence at Oak Investment Partners. He is an author of a number of scientific publications and named inventor on several patents.

Dr. Pruzanski received his M.D. from McMaster University in Hamilton, Canada, a M.A. degree in International Affairs from the Johns Hopkins University School of Advanced International Studies in Bologna, Italy and Washington, D.C., and a bachelor’s degree in Political Science from McGill University in Montreal, Canada.